Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807844 · ClinicalTrials.gov registry record · Phase 1
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
NCT02807844 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 141 participants.
The verdict
NCT02807844, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.
Interventions
- DRUG PDR001
- DRUG MCS110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2016-06-29 |
| Est. Completion | 2020-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02807844
The ClinicalTrials.gov registry entry for NCT02807844 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PDR001 is the first listed.
NCT02807844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02807844 about?
NCT02807844 is a clinical study titled "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies". The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.
What is the current status of trial NCT02807844?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2016-06-29. Estimated completion is 2020-06-04.
What interventions are being tested in trial NCT02807844?
The interventions under investigation include: PDR001 (DRUG), MCS110 (DRUG).
Who is sponsoring clinical trial NCT02807844?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.